A compact GAD67 promoter enables inhibitory neuron-targeted AAV gene therapy for seizure suppression
Molecular Therapy · 2026
DOI: 10.1016/j.ymthe.2026.06.007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2026. Verfasst von Yuuki Fukai und 5 weiteren Autor:innen. Beteiligte Einrichtung: Viral Vector Core, Gunma University, Initiative for Advanced Research, Maebashi, Gunma 371-8511, Japan; Department of Neurophysiology & Neural Repair…. Hauptthemen laut MEDLINE: Glutamate Decarboxylase, Promoter Regions, Genetic, Dependovirus, Genetic Vectors. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development, Gunma University.
Abstract (Originalsprache)
Epilepsy arises from disruption of excitation-inhibition (E/I) balance, typically due to excessive excitatory activity. Despite available therapies, a substantial proportion of patients remain treatment resistant. Enhancing inhibitory neuron activity via gene therapy can restore E/I balance and may therefore provide a therapeutic strategy for treatment-resistant epilepsy. Here, we developed a compact 410-bp glutamic acid decarboxylase 67 promoter (cmGAD67) that enables strong, selective transgene expression in inhibitory neurons while preserving adeno-associated virus (AAV) packaging capacity. Systemic delivery of AAV vectors carrying cmGAD67 preferentially targeted parvalbumin interneurons and enabled efficient circuit modulation. To evaluate therapeutic potential, we expressed glutamic acid decarboxylase 65 (GAD65) under the control of cmGAD67 (AAV-GAD65). AAV-GAD65 suppressed abnormal delta oscillations, reduced seizure-like activity, normalized anxiety-like behavior, and improved survival in seizure models. Biochemical analyses confirmed increased GABA levels in the cortex and hippocampus, linking functional improvements to enhanced inhibitory neurotransmitter synthesis. Together, these findings establish the cmGAD67 promoter as a versatile platform for inhibitory neuron-targeted AAV gene delivery and identify AAV-GAD65 as a promising strategy for seizure control and disorders associated with E/I imbalance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Viral Vector Core, Gunma University, Initiative for Advanced Research, Maebashi, Gunma 371-8511, Japan; Department of Neurophysiology & Neural Repair, Gunma University Graduate School of Medicine, Maebashi, Gunma 371-85…
- Department of Neurophysiology & Neural Repair, Gunma University Graduate School of Medicine, Maebashi, Gunma 371-8511, Japan.
- Medical Genetics Research Center, Nara Medical University, 840 Shijo-Cho, Kashihara, Nara 634-8521, Japan.
Förderung
- Japan Society for the Promotion of Science
- Japan Agency for Medical Research and Development
- Gunma University
Zitieren
APA
Fukai, Y., Konno, A., Hosoi, N., Miyakawa, K., Kaneko, R., & Hirai, H. (2026). A compact GAD67 promoter enables inhibitory neuron-targeted AAV gene therapy for seizure suppression. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2026.06.007
Vancouver
Fukai Y, Konno A, Hosoi N, Miyakawa K, Kaneko R, Hirai H. A compact GAD67 promoter enables inhibitory neuron-targeted AAV gene therapy for seizure suppression. Molecular Therapy. 2026. doi:10.1016/j.ymthe.2026.06.007
BibTeX
@article{Fukai2026,
author = {Fukai, Yuuki and Konno, Ayumu and Hosoi, Nobutake and Miyakawa, Karin and Kaneko, Ryosuke and Hirai, Hirokazu},
title = {A compact GAD67 promoter enables inhibitory neuron-targeted AAV gene therapy for seizure suppression},
journal = {Molecular Therapy},
year = {2026},
doi = {10.1016/j.ymthe.2026.06.007}
}
EUVIMED